Anacor Pharmaceuticals Inc (ANAC) reported quarterly earnings results on Tuesday, May-10-2016. The company reported $-0.36 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $-0.35. The company posted revenue of $17.54 million in the period, compared to analysts expectations of $18.66 million. The company’s revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.30 EPS.
Many Wall Street Analysts have commented on Anacor Pharmaceuticals Inc. Shares were Reiterated by Wedbush on May 3, 2016 to “Outperform” and Lowered the Price Target to $ 148 from a previous price target of $152 .Mizuho Initiated Anacor Pharmaceuticals Inc on Mar 11, 2016 to “Buy”, Price Target of the shares are set at $103.
Anacor Pharmaceuticals Inc opened for trading at $58.18 and hit $60.36 on the upside on Friday, eventually ending the session at $58.7, with a gain of 0.19% or 0.11 points. The heightened volatility saw the trading volume jump to 14,60,679 shares. Company has a market cap of $2,633 M.
In a different news, on Apr 29, 2016, Ryan T Sullivan (EVP and General Counsel) sold 3,125 shares at $66.33 per share price. According to the SEC, on Apr 11, 2016, Anders D Hove (director) sold 229,301 shares at $72.29 per share price. On Mar 23, 2016, Paul L Berns (President and CEO) sold 37,500 shares at $60.17 per share price, according to the Form-4 filing with the securities and exchange commission.
Anacor Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on discovering developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company’s lead product candidate AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Company’s product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development which include AN3365. The Company’s compound AN5568 (SCYX-7158) is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).